Neuroimmune Modulation Platform
Relapsing-Remitting Multiple Sclerosis
Key Facts
About SetPoint Medical
SetPoint Medical is a private, commercial-stage biotech company that has successfully developed and gained FDA approval for the first device-based neuroimmune modulation therapy for rheumatoid arthritis. The company's core technology, the SetPoint System, represents a paradigm shift in autoimmune disease treatment by leveraging bioelectronic medicine to modulate the inflammatory response via the vagus nerve. With a landmark publication in Nature Medicine and recent CMS reimbursement approval, SetPoint is positioned to commercialize its RA therapy while advancing its platform into new indications, including multiple sclerosis. The company is backed by significant private financing, including a recent $140 million round, to support its launch and pipeline expansion.
View full company profile